If you were diagnosed with psoriasis 20 years ago, your options were topical steroids, methotrexate, and UV therapy. Today, there are over 15 distinct treatment approaches spanning topicals, traditional oral medications, small molecule oral agents, injectable biologics, and — as of 2025 — the first-ever oral biologic (ICOTYDE). The challenge is no longer finding a treatment that works. It is choosing the right one for your disease severity, lifestyle, budget, and risk tolerance.
The Psoriasis Treatment Ladder
Dermatologists generally follow a stepped approach based on disease severity:
- Mild psoriasis (BSA <3%): Topical treatments are first-line
- Moderate psoriasis (BSA 3–10%): Topicals + phototherapy, or escalate to systemic therapy
- Moderate-to-severe psoriasis (BSA >10% or significant quality-of-life impact): Systemic therapy — biologics, oral agents, or both
BSA = Body Surface Area affected. One palm (including fingers) equals roughly 1% BSA.
Topical Treatments
Topicals remain the foundation for mild psoriasis and as adjunct therapy for moderate-to-severe disease.
| Medication | Type | Best For | Key Considerations |
|---|---|---|---|
| Betamethasone dipropionate | Potent corticosteroid | Flare control, body plaques | Effective but should not be used long-term (skin thinning risk) |
| Calcipotriene (Dovonex) | Vitamin D analog | Maintenance therapy | Slower onset; safe for long-term use; often combined with steroids |
| Calcipotriene/betamethasone (Enstilar, Wynzora) | Combination | Moderate plaques | Best topical efficacy data; use for up to 8 weeks |
| Tazarotene | Retinoid | Thick plaques | Can be irritating; effective for scaling |
| Tacrolimus/pimecrolimus | Calcineurin inhibitors | Face and skin folds | No steroid side effects; good for sensitive areas |
| Roflumilast cream (Zoryve) | PDE4 inhibitor | Body and scalp psoriasis | Non-steroidal; approved for plaque psoriasis; once-daily application |
| Tapinarof (Vtama) | Aryl hydrocarbon receptor agonist | Plaque psoriasis | Non-steroidal; novel mechanism; no limit on treatment duration |
The newest topicals — roflumilast (Zoryve) and tapinarof (Vtama) — are significant because they offer non-steroidal options with no treatment duration limits. This solves the biggest problem with topical steroids: the need to take breaks to avoid skin thinning.
Traditional Oral Systemic Medications
These older systemic agents remain relevant, especially when cost or access limits biologic use:
| Medication | Mechanism | PASI 75 Response | Key Risks | Monthly Cost |
|---|---|---|---|---|
| Methotrexate | Antimetabolite | 35–45% | Liver toxicity, bone marrow suppression; requires lab monitoring | $10–$30 (generic) |
| Cyclosporine | Calcineurin inhibitor | 50–70% | Kidney toxicity, hypertension; limited to 1–2 years of use | $100–$300 (generic) |
| Acitretin (Soriatane) | Retinoid | 25–40% | Teratogenicity (absolutely contraindicated in pregnancy), lipid elevation, hair loss | $200–$500 |
Methotrexate remains the most prescribed oral systemic because it is inexpensive and many dermatologists are comfortable managing it. But its efficacy pales compared to modern biologics, and the liver toxicity monitoring burden is significant.
Modern Small Molecule Oral Agents
These newer oral medications offer better safety profiles than traditional systemics, though efficacy still falls below injectable biologics:
| Medication | Mechanism | PASI 75 Response | Key Benefits | Key Risks | Monthly Cost |
|---|---|---|---|---|---|
| Apremilast (Otezla) | PDE4 inhibitor | 30–40% | No lab monitoring required; well-tolerated | GI side effects (diarrhea, nausea); modest efficacy | $1,800–$2,500 |
| Deucravacitinib (Sotyktu) | TYK2 inhibitor | 55–60% | Better efficacy than Otezla; minimal lab monitoring | Upper respiratory infections; acne | $2,000–$3,000 |
| ICOTYDE (icotrokinra) | Oral IL-23 inhibitor (oral biologic) | 70–80% | First oral biologic; efficacy approaching injectable biologics | New drug — long-term data still accumulating | ~$3,500 (estimated) |
ICOTYDE is the breakthrough in this category. As the first-ever oral biologic — an IL-23 inhibitor taken as a pill rather than injected — it delivers biologic-level efficacy without injections. In clinical trials, ICOTYDE achieved PASI 75 responses in approximately 75% of patients, rivaling injectable IL-23 inhibitors like Skyrizi and Tremfya. See our detailed ICOTYDE guide for more.
Injectable Biologics
Biologics remain the gold standard for moderate-to-severe psoriasis. The IL-23 inhibitors currently lead the field in efficacy and convenience:
IL-23 Inhibitors (Current Gold Standard)
| Medication | Dosing | PASI 90 Response | Notable Features |
|---|---|---|---|
| Risankizumab (Skyrizi) | Every 12 weeks (after loading) | 72–75% | Best-in-class durability; convenient dosing; PASI 100 rates approaching 40% |
| Guselkumab (Tremfya) | Every 8 weeks (after loading) | 65–73% | Strong long-term data; also approved for psoriatic arthritis |
| Tildrakizumab (Ilumya) | Every 12 weeks (after loading) | 55–62% | Good safety profile; less efficacious than Skyrizi/Tremfya |
IL-17 Inhibitors
| Medication | Dosing | PASI 90 Response | Notable Features |
|---|---|---|---|
| Secukinumab (Cosentyx) | Monthly (after loading) | 65–70% | Extensive long-term safety data; also treats ankylosing spondylitis |
| Ixekizumab (Taltz) | Every 4 weeks (after loading) | 68–73% | Fast onset of action; also treats psoriatic arthritis |
| Bimekizumab (Bimzelx) | Every 4–8 weeks | 75–85% | Dual IL-17A/F inhibitor; highest PASI 90 rates; oral candidiasis risk |
| Brodalumab (Siliq) | Every 2 weeks | 70–75% | IL-17 receptor blocker; REMS program due to rare suicidality signal |
TNF Inhibitors (Older Biologics)
TNF inhibitors — adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), certolizumab (Cimzia) — were the first biologics for psoriasis and are still used, especially for patients who also have psoriatic arthritis. However, their efficacy is lower than IL-17 and IL-23 inhibitors, and they are no longer first-line for psoriasis-only patients.
The exception: biosimilars of Humira (adalimumab) have made TNF inhibitors much more affordable, which may make them reasonable starting options for patients with cost concerns.
How to Choose the Right Treatment
By Disease Severity
- Mild (BSA <3%): Start with topicals (calcipotriene/betamethasone combo, or Zoryve/Vtama for steroid-free options)
- Moderate (BSA 3–10%): Topicals + Sotyktu or ICOTYDE. Consider a biologic if oral options are insufficient.
- Moderate-to-severe (BSA >10%): Biologics are first-line. Skyrizi and bimekizumab lead in efficacy data.
By Patient Preference
- "I hate needles": ICOTYDE (oral biologic with biologic-level efficacy), Sotyktu, or Otezla
- "I want the strongest option": Bimekizumab (Bimzelx) or risankizumab (Skyrizi)
- "I want minimal dosing": Skyrizi (every 12 weeks) or Ilumya (every 12 weeks)
- "I have psoriatic arthritis too": IL-17 inhibitors or TNF inhibitors (dual indication coverage)
- "Cost is my main concern": Methotrexate or adalimumab biosimilar
By Insurance Coverage
Insurance formulary placement heavily influences which biologic is the practical best choice. Most insurers require step therapy — trying and failing a preferred agent before approving a non-preferred one. Check with your insurance before assuming access to any specific biologic. ICOTYDE, as a new drug, may have more restrictive prior authorization during its first year on the market.
Cost Landscape in 2026
| Treatment Type | Monthly Cost Range (List Price) | With Insurance | Manufacturer Assistance |
|---|---|---|---|
| Topicals (generic steroids) | $10–$50 | $0–$25 copay | N/A |
| Topicals (Zoryve, Vtama) | $800–$1,200 | $0–$75 copay | Yes (copay cards) |
| Methotrexate | $10–$30 | $0–$10 | N/A |
| Otezla | $1,800–$2,500 | $0–$75 copay | Yes (copay card) |
| Sotyktu | $2,000–$3,000 | $0–$75 copay | Yes (copay card) |
| ICOTYDE | ~$3,500 | TBD (new drug) | Yes (patient assistance) |
| Injectable biologics | $3,000–$7,000 | $0–$150 copay | Yes (most have copay programs) |
| Adalimumab biosimilars | $1,200–$2,500 | $0–$75 copay | Varies |
Bottom Line
The psoriasis treatment landscape in 2026 offers unprecedented options. The arrival of ICOTYDE as the first oral biologic is a genuine paradigm shift for patients who want biologic-level efficacy without injections. For patients who need the absolute highest clearance rates, bimekizumab and risankizumab lead the injectable field. And for those managing cost, biosimilar adalimumab and generic methotrexate remain viable.
The best psoriasis medication is the one that clears your skin, fits your lifestyle, and is financially sustainable. Work with your dermatologist to navigate insurance requirements and find the right fit.
For more detailed comparisons, see our guides on ICOTYDE vs Skyrizi, ICOTYDE vs Tremfya, and switching from injectable to oral psoriasis treatment.